Li Wang

机构：Shanghai Jiao Tong University, Ruijin Hospital, First People's Hospital of Yunnan Province, Shanghai Institute of Nutrition and Health, Sichuan Cancer Hospital, Shanghai Institute of Hematology, First Affiliated Hospital of Zhengzhou University, University of Chinese Academy of Sciences · ORCID：0000-0003-2452-0169

发表论文 143 篇 · 总被引 2280 次 · h-index 26

代表论文

• Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis (2025 · Phytomedicine · 被引 8)
• A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma (2025 · Blood · 被引 5)
• Treatment-related adverse events, immune-related adverse events and discontinuation in patients with solid tumors adding adjuvant immune checkpoint blockade: a meta-analysis of 38 randomized controlled trials (2025 · International Journal of Surgery · 被引 5)
• Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure (2025 · Frontiers in Immunology · 被引 2)
• Mechanistic insights into Schisandrin C as the active anti-renal fibrosis ingredient of Schisandra chinensis: a network pharmacology analysis and transcriptomics integrated experimental verification (2025 · Naunyn-Schmiedeberg s Archives of Pharmacology · 被引 2)
• CRP and HNF1A collaborate to regulate the progression of laryngeal cancer through the Wnt signaling pathway (2025 · Functional & Integrative Genomics · 被引 1)